Precision medicine in oncology: a complicated idea needs a simple solution by Benson, Adam
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2016
Precision medicine in oncology: a




	  BOSTON  UNIVERSITY  
  











PRECISION  MEDICINE  IN  ONCOLOGY:  A  COMPLICATED  











ADAM  RYAN  BENSON  
  







Submitted  in  partial  fulfillment  of  the  
  
requirements  for  the  degree  of  
  
Master  of  Science  
  
2016  









































   ©  2016  by  
      ADAM  RYAN  BENSON  
      All  rights  reserved  













First  Reader   ___________________________________________  
   Hee-­Young  Park,  Ph.  D.  
   Assistant  Dean  of  Graduate  Medical  Sciences  









Second  Reader   ___________________________________________  
   Deborah  Morosini,  M.D.,  M.S.W.  
   Foundation  Medicine,  Inc.    
   Vice  President,  Clinical  Development  











   I  dedicate  this  work  to  anyone  who  believes  things  do  not  need  to  first  be  

















   For  25  of  my  30  years,  I  have  been  on  the  receiving  end  of  an  
immeasurable  amount  of  support  in  my  pursuit  to  learn  more  about  the  world  
around  me.  I  want  to  acknowledge  family,  friends  and  especially  those  who  have  
mentored  me  on  this  wild  ride.  In  recognition,  I  look  forward  to  spending  the  next  


































PRECISION  MEDICINE  IN  ONCOLOGY:  A  COMPLICATED  
IDEA  NEEDS  A  SIMPLE  SOLUTION  
  




     
   Cancer  therapy  has  historically  been  determined  by  a  tumor’s  tissue  of  
origin.  Now,  thanks  to  advances  in  genomics  technology,  scientists  are  looking  
further  into  one’s  cancer;;  into  the  very  genome  that  drives  the  tumor  growth.  
The  growth  of  genomics  in  cancer  research  has  been  astronomical.  In  a  
little  over  ten  years  since  the  completion  of  the  Human  Genome  Project,  genomic  
profiling  technologies  have  developed  into  an  incredibly  powerful,  relatively  
cheap,  and  immensely  underutilized  tool  for  oncologists.    
In  the  midst  of  the  advances  in  cancer  profiling,  there  has  been  reluctance  
from  oncologists  to  incorporate  genomic  profiling  into  their  treatment  decisions.  
Saddled  by  outdated  clinical  trial  designs,  and  cancer  drug  regulation  programs,  
the  true  measure  of  the  clinical  utility  of  genomic  profiling  has  yet  to  be  seen.  
Cancer  scientists  will  continue  to  profile  cancers  at  a  pace  well  beyond  the  limits  
of  the  field  of  oncology.  Without  coordinated  efforts  to  update  the  oncology  
healthcare  system,  compendia  of  data  will  continue  to  be  generated  with  limited  
ability  to  translate  the  information  into  personalized  medicines.    
There  are  significant  barriers  to  overcome  before  genomic  data  can  
universally  be  incorporated  into  the  daily  practice  of  cancer  medicine.  In  the  
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meantime,  resources  are  available  for  physicians  to  help  begin  the  process  of  
integrating  a  more  personalized  approach  to  cancer  therapy.  Third-­party  
bioinformatics  companies  are  in  the  best  position  to  be  the  agents  of  this  change.  
As  cancer  research  continues  to  adopt  a  genomic  approach,  it  is  paramount  that,  
for  the  sake  of  millions  of  cancer  patients,  the  healthcare  system  adapts  in  a  way  
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The  Human  Genome  Project,  completed  in  2003,  revolutionized  our  
understanding  of  the  cancer  genome.  The  cost  of  the  project,  where  the  first  
human  genome  was  read,  is  reported  to  be  as  high  as  $3  billion  (Hayden,  2014).    
A  little  more  than  10  years  later,  genomic  profiling  companies  like  Illumina  
(San  Diego,  CA)  are  close  to  achieving  the  $1,000  genome  (Hayden,  2014),  
dropping  the  cost  of  sequencing  the  human  genomic  over  99%  within  a  decade.    
Spurred  by  the  sudden,  and  significant  decrease  in  costs  associated  with  
sequencing  the  human  genome,  subsequent  efforts  have  since  been  made  to  go  
well  beyond  just  the  reading  of  one’s  genome.  The  Cancer  Genome  Atlas  and  its  
goal  to  completely  categorize  select  cancers  is  just  one  initiative  driven  by  fervent  
interest  in  cancer  genomics  (Vicini  et.  al.,  2015).    
While  genomics  has  afforded  the  field  of  research  oncology  the  ability  to  
view  cancer  under  a  much  more  powerful  lens,  the  pace  at  which  cancer  
scientists  today  are  incorporating  new  information  and  technologies  is  well  
beyond  the  bandwidth  of  our  current  healthcare  system  (Kibbe,  2015).  The  
implementation  of  genomics  into  cancer  profiling  and  the  subsequent  
computation  of  the  compendia  of  data,  utilizing  new  algorithms,  have  uncovered  
novel  changes  in  many  different  canonical  signaling  pathways,  furthering  our  
understanding  of  cancer  as  a  whole  (Chmielecki  &  Meyerson,  2014).  Yet,  while  
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we  are  now  in  a  position  to  know  this  information,  currently  healthcare,  as  a  
whole,  is  limited  in  its  ability  to  act  on  this  information.    
Oncology  care  today  is  plagued  by  outdated  treatment  approaches,  
clinical  trial  systems,  drug  approval,  and  reimbursement  guidelines.  Furthermore,  
advances  in  genomic  research  suffer  from  poor  uptake  as  many  of  today’s  
oncologists  are  ill-­equipped  to  handle  the  new  information.  Improving  genomic  
medical  education,  or  drug  approval  regulation  alone  will  not  be  enough.  A  fully  
realized  revolution  in  the  field  of  cancer  genomics  will  need  comprehensive  
updates  across  all  aspects  of  cancer  care  (Garraway,  2013)  -­-­  updates  that  will  
take  time.    
Perhaps  the  most  important  change  to  occur  in  the  coming  years  will  be  
an  increased  reliance  on  the  very  companies  that  provide  comprehensive  
genomic  profiling.  In  the  short  term,  the  world  of  oncology  will  be  in  flux,  as  new  
genomics-­driven  approaches  filter  into  cancer  care,  and  while  tissue-­based  
approaches  filter  out.  As  cancers  become  more  thoroughly  profiled,  cancers  that  
are  rare  to  the  individual  healthcare  provider  will  not  be  unique  to  the  centralized  
bioinformatics  company  that  does  the  profiling.  When  oncologists  order  a  test  
from  a  company  like  Foundation  Medicine,  they  will  not  only  rely  on  the  
bioinformatics  company  to  create  a  unique  patient  report,  but  also  in  how  they  
utilize  a  database  of  information  to  provide  context  to  a  patient’s  tumor  type  that  
a  physician  may  be  unfamiliar  with  (Foundation  Medicine,  2016).    
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New  technologies  are  helping  pharmaceutical  companies  discover  new  
and  effective  therapies  that  target  specific  genomic  alterations.  In  order  for  
physicians  to  continue  delivering  high-­quality  care  to  their  patients,  this  will  
require  physicians  to  adapt  to  these  new  approaches.  Together,  with  
bioinformatics  partners,  physicians  can  help  usher  in  a  new  phase  of  oncology  
medicine;;  the  precision  medicine  movement.    
  
HISTORY  OF  CANCER  
   In  the  simplest  form,  cancer  is  defined  as  abnormal  growth  (Mendelsohn  
et.  al.,  2015).  Abnormal  growths  can  be  seen  in  daily  life  as  bumps  and  bruises  
from  contact  injuries  or  even  goiters  brought  on  by  low  iodine  in  the  diet.  
However,  in  the  case  of  cancer,  abnormal  growths  are  brought  on  by  a  complex  
build  up  of  cellular  growth.  Cancer  can  take  on  all  shapes  and  sizes,  and  range  
from  a  benign  adenoma  polyp  in  the  colon  to  a  highly  malignant  melanoma  of  the  
skin  (Mendelsohn  et.  al.,  2015).  The  word  ‘cancer’  itself  conjures  up  the  sense  of  
complexity.  Aptly  so,  as  it  turns  out  to  be  as  complex  as  the  cellular  processes  
associated  with  it.  
Hippocrates,  the  “father  of  medicine”,  is  credited  as  invoking  the  image  of  
a  crab  when  considering  the  insidious  pathological  behavior  of  cancer  in  the  
body,  using  the  terms  carcinoma  to  define  non-­ulcer  and  ulcer  forming  tumors  
respectively  (Hajdu,  2011).  Centuries  later,  another  Greek  phyisician,  Galen  –  a  
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surgeon  to  the  gladiators  -­  would  go  on  to  describe  the  swellings  and  fleshy  
tumors  as  sarcomas  (Hajdu,  2011).  The  two  descriptions  have  held  on  for  more  
than  two  millennia  as  Hippocrates  crab-­derived  terminology  are  used  in  today’s  
clinic  to  describe  malignant  tumors,  whereas  Galen’s  descriptor  of  cancer  growth  
has  gone  on  to  become  the  basis  for  the  cancer  specialty  in  medicine;;  oncology.    
The  Renaissance  brought  with  it  fevered  interest  in  gaining  a  greater  
understanding  of  the  human  body.  For  centuries,  the  humoral  theory  prevailed  as  
the  preeminent  theory  of  disease.  With  lessening  constrictions  held  forth  by  the  
Church,  a  more  invasion  review  of  the  body  became  permitted  and  the  practice  
of  performing  autopsies  grew.  As  made  famous  by  Rembrandt’s  1632  painting  
The  Anatomy  Lesson  of  Dr.  Nicolaes  Tulp,  anatomy  lessons  rose  to  become  a  
social  event  (Ijpma  et.  al.,  2006).  As  scientists  of  this  period  began  to  instill  the  
scientific  method  into  their  practices,  one  man,  in  a  town  west  of  Venice,  Italy,  
started  a  practice  that  would  carry  on  as  today’s  pathologic  review  of  the  body.  In  
1761,  Giovanni  Morgagni  of  Padua  was  the  first  to  use  autopsies  to  connect  the  
patient’s  illness  to  pathologic  findings  (Hajdu,  2012).  It  was  around  this  time,  a  
century  prior  to  the  development  of  anesthesia,  that  a  Scottish  surgeon,  John  
Hunter  proposed  that  certain  cancers  could  be  resected,  as  long  as  they  have  
not  yet  spread  to  nearby  tissue.  It  would  be  the  19th  century,  with  the  advent  of  
anesthesia  and  the  microscope  before  this  theory  truly  took  off.    
   As  interest  in  this  field  grew,  new  theories  toward  pathological  states  were  
adopted.  Unfortunately  for  many,  one  such  theory  –  the  contagion  theory  -­  was  
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borne  out  of  Holland  by  doctors  Lusitani  and  Tulp  (Hajdu,  2011).  Without  the  
luxury  of  modern  genomics,  Lusitani  and  Tulp  reasoned  that  as  many  women  of  
the  same  household  suffer  from  breast  cancer  cancer  must  be  contagious.  
Throughout  the  mid-­  to  late-­17th  century,  the  contagion  theory  took  hold  
throughout  Europe,  forcing  cancer  patients,  and  eventually  cancer  hospitals  
outside  of  the  city  limits  (Hajdu,  2011).    Other,  now  preposterous,  theories  sprung  
up  at  this  time.  The  trauma  theory  is  just  one  example.  Though  unable  to  be  
reproduced,  the  theory  proposed  that  cancer  came  from  significant  traumas  
sustained  (Hajdu,  2012).    
Around  this  time,  the  lymph  theory,  as  supported  by  famed  surgeon  John  
Hunter,  was  rooted  in  the  loss  of  fluid  homeostasis.    The  lymph  theory  purported  
that  cancerous  tumors  grew  from  lymph  which  was  cast  aside  by  the  body’s  
blood  (Suhakar,  2009).    
In  the  1800’s  Rudolf  Virchow,  the  father  of  cellular  pathology,  took  what  
Morgagni  learned,  linking  autopsy  findings  with  one’s  illness,  and  used  the  newly  
developed  microscope  to  connect  cellular  pathology  to  disease  (Hajdu,  2012).  
The  discovery  that  cancer  was  made  up  of  cells,  and  not  lymph,  was  made  by  
pathologist  Johannes  Muller,  and  with  it  came  the  end  of  the  lymph  theory.  With  
increased  use  of  the  microscope,  Muller  and  Virchow  became  proponents  of  a  
cell-­based  theory  of  the  cancer  formation.  Cancers  were  then  classified  as  to  
how  they  looked  under  the  microscope.  In  the  clinic,  surgical  oncologists  and  
resident  pathologists  started  to  work  together  in  order  to  improve  outcomes  from  
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tumor  resections.  Surgeons  would  provide  tissue  samples  –  biopsies  –  of  the  
tumor  and  the  pathologist  could  use  the  microscope  to  characterize  the  
cancerous  growth  (Hajdu,  2012).  Over  a  century  later,  the  subjective  tissue-­
based  analysis  remains  the  bedrock  of  all  pathologic  review  of  cancer  cases  
(Kumar,  Srivastava  &  Srivastava,  (2015).    
   In  the  past  few  decades  the  world  of  oncology  has  seen  yet  another  
paradigm  shift  as  cancer  sub-­classifications  were  born.  The  discovery  of  tumor  
biomarkers,  specifically  the  discovery  of  a  proto-­oncogene  in  breast  cancer,  lead  




   In  1978,  the  epidermal  growth  factor  EGFR  (ErbB-­1,  HER1)  was  first  
discovered  (Kumar  &  Badve,  2008).  As  the  first  receptor  tyrosine  kinase  
identified,  it  set  the  stage  for  the  mammalian  version  of  the  virus-­bred  gene  
HER2  to  be  cloned,  between  1984  and  1986  (Kumar  &  Badve,  2008).  A  few  
years  later,  American  scientists  (Genentech,  CA)  were  able  to  characterize  
antibodies  that  were  reactive  to  EGFR  or  its  HER2  gene  product  (Kumar  &  
Badve,  2008).    In  1991,  a  year  after  the  antibodies  were  characterized,  
Genentech  opened  clinical  trials  for  its  monoclonal  antibody  trastuzumab  
(HerceptinTM)  and  seven  years  later,  HerceptinTM  was  released  to  the  market.    
Suddenly,  breast  cancer  became  the  first  cancer  to  be  treated  successfully  with  
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molecularly-­targeted  therapy  (Kumar  &  Badve,  2008).    
   The  discovery  of  HER2  as  a  targetable  breast  cancer  biomarker  helped  
usher  in  new  processes  of  subdividing  anatomical  organization  by  biomarker  
status.  Breast  cancers  were  then  not  just  treated  as  breast  cancer,  but  instead  as  
HER2+  or  HER-­  cancers  (Kumar  &  Badve,  2008).    Those  with  HER2+  cancer  
could  now  be  treated  with  a  drug  that  targets  a  specific  protein  overexpression  
(Fig  A).    Considering  15-­20%  of  all  breast  cancers  are  HER2+,  the  discovery  of  
trastuzumab  as  an  effective  alternative  to  cytotoxic  chemotherapy  regimens  
proved  to  be  an  essential  key  that  opened  the  door  of  oncology  to  the  world  of  














Figure  1.  Current  guidelines  for  breast  cancer  treatment.  
 
(From  Senkus  et.  al.,  2015)  
   Few  likely  grasped  the  influence  these  initial  discoveries  of  targetable  
biomarkers  would  have  on  the  future  of  genomic  medicine.  Their  presence  alone  
was  a  sign  of  potentially  a  multitude  of  underlying  tumor-­driving  alterations  in  the  
tumor’s  genome  (Hertz  &  McLeod,  2016).  In  the  years  since,  scientists  have  
used  comprehensive  genetic  analyses  of  different  cancers  to  learn  that  it  is  not  
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just  a  few  alterations  that  drive  cancer,  but  rather  many  thousands  that  can  be  
found  in  essentially  a  handful  of  canonical  oncogenic  pathways  (Hertz  &  McLeod,  
2016).  Examples  of  these  pathways  were  published  by  Hanahan  and  Weinberg  
(2011)  in  an  update  to  their  year  2000  perspective.  In  it,  the  authors  describe  six  
major  ‘hallmarks’  of  cancer  as  the  following:  1.)  the  release  of  angiogenic  factors  
into  the  immediate  area  around  the  cell;;  2.)  cells  that  are  inherently  immune  to  
endogenous  cell  death  factors;;  3.)  the  sustained  release  of  signals  that  drive  cell  
proliferation;;  4.)  the  ability  to  block  growth  suppressors;;  5.)  the  ability  to  enable  
replicative  immortality;;  and  6.)  activation  of  mechanisms  that  allow  invasion  into  
other  tissues  and  eventual  metastasis  (Hanahan  &  Weinberg,  2011).    
   In  the  years  since  their  publication,  what  has  troubled  cancer  scientists  and  
oncologists  alike  is  the  notion  put  forth  by  Drs.  Hanahan  and  Weinberg  (2011)  
that  cancer  cells  will  not  typically  utilize  just  one  of  these  hallmarks,  but  rather  
any  number  of  combinations  of  the  six  listed.  Thus,  because  not  all  cancer  cell  
proliferation  will  rely  entirely  on  proliferation  signaling,  the  introduction  of  an  
EGFR  inhibitor  is  likely  to  be  ineffective  in  many  cancer  cell  types.  In  order  to  
better  understand  the  pathways  associated  with  different  cancers,  scientists  have  
been  turning  to  genomics.  In  order  to  understand  how  genomics  are  being  used  
to  solve  this  problem,  it’s  important  to  know  what  can  be  gained  by  running  a  
genomic  analysis  on  one’s  tumor.    
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GENOMICS  IN  CANCER  
 
Cancer  cells  rely  on  cellular  processes  driven  by  the  DNA  blueprint.  Thus,  
deviations  of  the  individual  base  pairs  from  a  normal  coding  region  of  a  gene  in  
the  DNA  strand  can  surreptitiously  cause  different,  irregular  cellular  processes  to  
take  over  (Lodish  et.  al.,  2012).    There  are  many  different  ways  the  genetic  code  
within  a  cancer  cell  can  change.  For  example,  an  alteration  caused  by  one  DNA  
base  pair  taking  the  place  of  another  is  called  a  missense  mutation  and  often  
leads  to  an  amino  acid  substitution  and  a  subsequent  change  in  protein  
(Chmielecki  &  Meyerson,  2014).  When  that  base  pair  rearrangement  occurs,  but  
instead  causes  a  stop  codon  to  truncate  the  length  of  a  gene,  this  is  called  a  
nonsense  mutation.  Other  ways  a  gene  can  be  altered  are:  an  incorrect  splice  
site  causing  a  shortened  gene  transcript;;  the  insertion  or  deletion  of  one,  or  a  
number  of  bases;;  as  well  as  alterations  that  result  in  same  proteins  to  be  built  as  
the  normal  transcript  -­  silent  mutations  (Chmielecki  &  Meyerson,  2014).    
Genomic  testing  aims  to  read  the  DNA  blueprint  of  the  cancer  cells,  
allowing  scientists  and  caregivers  to  work  backwards  to  understand  what  
deviations  have  led  to  the  specific  cancer  phenotype.  Whereas  protein  
expression  techniques  like  immunostaining  can  show  the  presence  of  a  certain  
protein  (i.e.  determining  if  a  tumor  is  HER+/-­),  genomic  profiling  goes  deeper  
(Frampton  et.  al.,  2013).  By  looking  at  the  genomic  alterations  of  a  tumor,  one  
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can  better  pinpoint  what  has  lead  to  specific  protein  expression,  or  a  specific  
cancer  phenotype.    
Interestingly,  it  is  not  just  the  type  of  alteration  that  is  of  interest,  but  also  
the  overall  number  of  mutations.  The  rate  in  which  tumors  present  mutations  to  
geneticists  can  vary  between  tumor  types.  Mutations  that  are  considered  
synonymous  (silent),  and  those  that  are  called  nonsynonymous  (nonsilent)  vary  
between  tumors  of  mesenchymal  origin  and  those  of  solid  epithelial  origin  
(Chmielecki  &  Meyerson,  2014).  Patients  who  present  with  mesenchymal  tumors  
like  rhabdoid  or  Ewing  sarcomas  typically  have  tumors  that  express  mutations  at  
the  low  end  of  the  spectrum,  at  a  rate  of  0.1  to  1  mutation  per  every  million  base  
pairs  (Figure  2).  On  the  high  end  of  the  spectrum,  cancers  of  tissues  that  are  
exposed  to  many  different  external  insults,  such  as  melanoma  of  the  skin  or  lung  
cancer,  can  have  tumors  with  a  mutation  load  of  10-­100  mutations  per  every  










Figure  2.  Mutation  rates,  shown  as  number  of  mutations  per  megabase,  across  
different  cancer  types  
  
(From  Chmielecki  &  Meyerson,  2014)  
  
   To  account  for  the  heterogeneity  across  these  different  cancers,  multiplex,  
comprehensive  genomic  profiling  was  developed  (Frampton  et.  al.,  2013).    
Whereas  “hot-­spot”  tests  or  “panel”  tests  interrogate  alterations  restricted  to  
specific  exons  and  codons,  comprehensive  genomic  profiles  can  use  the  same  
amount  of  starting  tissue  to  test  whole  exome  mutations,  insertions  and  
deletions,  translocations  and  fusions  and  copy  number  alterations  in  hundreds  of  





Figure  3.  Example  workflow  of  the  genomic  profiling  of  formalin-­fixed  paraffin-­
embedded  tumor  samples  
  
(From  Frampton  et.  al.,  2013)  
  
  
   The  recent  advances  in  understanding  these  genomic  changes  have  
offered  oncologists  not  only  a  better  view  into  their  patients’  genetic  blueprint,  but  
also  a  wealth  of  context  into  many  different  cancers.  Over  the  last  five  years  
alone,  the  collaborations  between  medical  academia,  bioinformatics,  and  
pharmaceutical  companies  have  been  a  boon  to  what  is  being  called  the  
precision  medicine  and  personalized  medicine  movements.    
  
START  OF  PRECISION  MEDICINE  
 
Throughout  scientific  literature,  these  two  terms  have  been  used  almost  
interchangeably  when  in  fact  they  convey  different  meanings.  Personalized  
medicine  is  the  use  of  cancer  genomic  data  to  tailor  treatments  directly  to  the  
individual  patient  (Garraway,  Verweij  &  Ballman,  2013).  Physicians  utilizing  
personalized  medicine  is  in  no  means  a  new  phenomenon.  For  decades,  
healthcare  providers  have  considered  one’s  diet,  exercise  and  environment,  to  
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guide  treatment  plans,  but  this  pales  in  comparison  to  the  level  of  personalization  
afforded  by  genomic  testing.  
   In  comparison  to  a  one-­drug-­for-­all  approach  –  seen  with  many  over-­the-­
counter-­medications  –  personalized  medicine  uses  information  available  to  not  
just  prescribe  select  medications  for  select  conditions,  but  to  also  tailor  the  
dosage  of  that  drug  knowing  that  not  all  patients  metabolize  drugs  the  same  way  
(Figure  4).  
  
Figure  4.  One-­dose-­fits-­all  versus  personalized  approaches  to  treatment    
  
(From  Xie  &  Frueh,  2005)  
  
  
While  personalized  medicine  focuses  on  the  patient,  precision  medicine  
looks  to  the  cancer  itself.  Precision  medicine  in  a  sense  is  much  more  technical.  
Precision  medicine  is  the  approach  wherein  enhanced  treatment  is  brought  forth  
by  the  implementation  of  improving  technologies.  The  precision  medicine  
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movement  aims  to  put  the  cancer  cell  blueprint  in  the  hands  of  both  the  
oncologist  and  cancer  researcher  to  bring  with  them  a  clearer  view  into  the  
cellular  processes  that  drive  tumor  pathology.  Bringing  less  speculation  to  
cellular  pathogenesis,  will  drive  the  personalized  medicine  movement  and  the  
goal  of  “right  patient,  right  drug,  right  dose,  right  time”.    
  
GROWTH  OF  GENOMICS  IN  CANCER  
 
The  completion  of  the  Human  Genome  Project  in  2003  brought  with  it  an  
explosion  in  worldwide  efforts  to  characterize  cancer  genomes  (Garraway  &  
Lander,  2013).  As  the  aperture  through  which  researchers  look  at  cancer  
narrows,  the  focus  of  the  physician  to  move  from  a  tissue-­based,  histological  
approach  to  something  more  genomics-­driven  has  yet  to  truly  be  widely  adopted    
While  researchers  have  evolved  from  looking  at  downstream,  cell-­wide  
processes,  to  focusing  on  the  upstream,  individual  cell  signals,  many  oncologists  
have  been  reluctant  to  change  their  standard  of  care  practices,  instead    waiting    
until    sufficient  proof  is  present  before  they  jump  on  the  genomics  bandwagon  
(Gray  et.  al.,  2014).  
   When  used,  genomics  in  today’s  oncology  clinic  is  primarily  focused  on  
the  use  of  “hot  spot”  genomic  testing,  which  looks  at  the  binary  status  of  one  or  
two  precise  targetable  alterations  (Van  Allen  et.  al.,  2013).  Simply  the  presence  
or  absence  of  a  single  genomic  alteration  has  often  been  sufficient  enough  to  
drive  treatment  decisions.  However,  research  has  shown  that  the  context  in  
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which  the  alteration  was  found  must  also  be  taken  into  consideration.  Namely,  if  
found  in  different  cancers,  genetic  aberrations  can  differ  in  their  response  to  a  
particular  drug.    Mutations  that  predict  being  responsive  to  a  drug  in  one  organ  
system  may  have  an  entirely  different  response  in  a  different  cancer  type.    For  
example,  RAF  inhibitors  in  BRAF  V600  mutant  melanoma  respond  differently  
than  in  BRAF  V600  mutant  colorectal  carcinoma  (Van  Allen  et.  al.,  2013).  
Therefore,  it  is  not  enough  to  look  at  simply  the  presence  or  absence  of  an  
alteration,  one  must  also  take  into  consideration  the  histology  and  anatomic  
location  of  the  tumor  as  well  as  other  relevant  clinical  information.  
   Furthermore,  in  the  case  of  certain  lung  cancers,  there  have  been  more  
than  100  different  primary  and  secondary  EGFR  mutations  described  in  NSCLC  
case  reports  (Forbes  et.  al.,  2011).    As  a  result,  a  patient’s  EGFR  mutant  lung  
adenocarcinoma  may  have  multiple  variants  of  EGFR  mutations  that  each  
respond  differently  to  EGFR  tyrosine  kinase  inhibitors  (Pao  et.  al.,  2005).    Not  
only  is  there  a  need  to  better  understand  the  cellular  pathways  associated  with  
the  tumor  pathogenesis,  but  also  the  clinical  consequences  of  each  genomic  
alteration.    The  future  is  moving  away  from  “hot  spot”  testing  where  one  must  test  
one  to  two  genes  at  a  time,  and  towards  more  comprehensive  genomic  testing;;  
massively  parallel  sequencing  of  hundreds  of  genes.    
As  the  next-­generation  functional  diagnostics  come  into  play  in  genomic  
medicine,  it  is  important  to  understand  that  there  is  still  limited  understanding  of  
how  cancer  presents  in  the  clinic,  and  especially  how  it  matches  with  what  is  
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categorized  by  both  the  geneticist  and  the  pathologist  (Friedman,  2015).  In  other  
words,  cancer  phenotypes  and  their  respective  genotypes  have  yet  to  be  fully  




The  treating  oncologist  lies  at  the  heart  of  implementing  genomics  into  the  
field  of  oncology.  
Irrespective  of  what  cancer  researchers  discover,  and  whichever  new  
therapies  pharmaceutical  companies  release,  the  employment  of  all  these  
resources  rests  entirely  on  the  physicians  in  the  clinic.    While  the  onus  is  on  the  
physician  to  make  the  treatment  decision  that  is  best  for  the  patient,  this  decision  
is  most  often  made  without  comprehensive  genomic  profiling  of  their  patient’s  
tumors  (Gray  et.  al.,  2014).  As  it  turns  out,  physicians  are  hesitant  to  embrace  
comprehensive  genomic  profiling.  
At  the  Dana  Farber  Cancer  Institute,  and  Brigham  and  Women’s  Hospital  -­  
two  of  the  leading  cancer  hospitals  in  the  United  States  -­  physicians  were  asked  
to  complete  a  questionnaire  on  their  confidence  in  genomics  prior  to  the  launch  
of  the  Dana  Farber  Cancer  Institute’s  new  multiplex  tumor  assay  OncoMap  (Gray  
et.  al.  2014).  The  OncoMap  assay  genomically  profiles  patient  tumors  for  471  
alterations  in  41-­cancer  related  genes.    As  an  internally  developed  assay,  it  will  
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no  doubt  be  marketed  as  a  centerpiece  to  treatment  decisions  at  the  Dana  
Farber  Cancer  Institute.        
Of  the  160  physicians  to  complete  the  questionnaire  from  between  
September  2011  and  January  2012,  76%  reported  that  they  had  not  ordered  
genomic  profiling  for  their  patients  (Gray  et.  al.  2014).  Even  after  the  launch  of  
Dana  Farber’s  own  next-­generation  tumor  sequencing  assay,  75%  of  study  
participants  reported  they  would  not  order  genomic  testing  for  most  of  their  
patients.  This  is  despite  73%  of  study  participants  believing  that  treatment  
options  for  patients  would  be  somewhat  or  greatly  increased  by  using  the  new  
multiplex  genomic  test  (Gray  et.  al,  2014).  Why  a  clinician  would  choose  NOT  to  
order  a  test  that  may  provide  more  options  for  his/her  patient  is  perplexing.  This  
perhaps  can  be  explained  by  the  study’s  finding  that  wanting  to  profile  many,  or  
most  of  their  patients  was  associated  only  with  higher  genomic  confidence  (Gray  
et.  al.,  2014).  Clinicians  whose  workplaces  have  high  volumes  of  cancer  patients  
do  note  higher  levels  of  confidence  in  medical  genomics  (Cox  et.  al.  2012).  
However,  a  study  found  that  many  physicians  (73%)  reported  more  
comprehensive  genomic  profiling  of  their  patients’  tumor  would  lead  to  more  time  
necessary  to  discuss  treatment  options  (Freedman  et.  al.  2003).  If  these  
physicians  are  located  at  a  workplace  with  high  patient  volumes,  the  cumulative  
amount  of  time  necessary  to  discuss  all  treatments  with  all  patients  may  be  a  
daunting  enough  image  to  limit  the  number  of  tests  ordered.      
The  hesitancy  seen  in  physicians  surrounding  their  use  of  genomic  
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information  is  most  likely  borne  from  their  lack  of  confidence  in  understanding  
how  genomics  plays  into  their  practice  of  medicine.  Twenty-­two  percent  of  those  
who  completed  a  questionnaire  on  use  of  multiplex  testing  at  Ivy  League-­
associated  hospitals  stated  that  they  were  not  very  confident  or  not  confident  at  
all  in  their  knowledge  of  genomics  (Gray  et.  al.,  2014).  This  should  be  noted  as  a  
worrisome  statistic  considering  that  these  hospitals  are  consistently  voted  as  
some  of  the  top  hospitals  in  their  field.    
Furthermore,  14%,  and  26%  of  these  physicians  expressed  the  same  
limited  ability  to  explain  genomic  concepts  to  patients,  and  ability  to  make  
treatment  recommendations  based  on  the  genomic  data,  respectively  (Gray  et.  
al.,  2014).  Another  study  looking  at  physicians’  attitudes  toward  genetic  testing  
reported  that  only  29%  of  today’s  physicians  felt  competent  enough  to  provide  
genetic  counseling  to  their  patients  (Freedman  et.  al.,  2003).  Not  only  do  these  
results  suggest  reasons  why  genomic  testing  is  currently  being  underutilized,  but  
they  also  point  to  a  greater  problem;;  there  is  a  clear  disconnect  between  
physicians  and  their  patients.  It  has  been  reported  that  almost  three-­quarters  of  
the  US  (72%)  would  look  to  their  doctor  if  they  needed  any  answers  to  questions  
about  genomics  (Mitka,  1998).  Patients  are  paying  the  price  for  this  reluctance,  
as  their  assumptions  about  their  physician’s  familiarity  and  competency  in  
genomics  does  not  match  reality.  As  oncologists  continue  to  be  cautious  in  
embracing  advances  in  understanding  genomics  and  its  role  in  patients’  tumors,  
this  apparent  divide  between  physicians  and  their  patients  is  likely  to  remain.  As  
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one  recent  high-­profile  publication  highlighted,  this  disconnect  goes  beyond  the  
clinic,  and  has  influenced  the  very  researchers  who  provide  the  scientific  
knowledge  upon  which  physicians  base  their  treatments.  
In  late  2015,  a  team  of  French  oncologists  published  a  study  that,  at  the  
time,  was  the  first  randomized  investigation  of  precision  therapy.  The  SHIVA  trial,  
which  used  monotherapies  to  target  specific  alterations  in  metastatic  cancers  
primarily  showed  that  the  use  of  targeted  therapies,  namely  those  that  were  
considered  off-­label  –  approved  in  a  cancer  type  different  to  the  patient  being  
treated  –  led  to  no  significant  improvement  in  progression-­free  survival  when  
compared  to  a  standard  “physician’s  choice”  therapy  (Le  Tourneau  et.  al.,  2015).  
The  SHIVA  trial  was  heralded  by  many  as  ‘proof’  that  a  physician’s  choice,  and  
not  that  generated  by  a  third-­party  genomic  test  was  the  best  way  to  have  
success  fighting  cancer  (Catenacci  et.  al.,  2015).  However,  on  the  other  end  of  
the  spectrum,  many  pro-­genomics  scientists  condemned  the  study  for  spreading  
misinformation  and  coming  to  improper  conclusions.  Since  its  publication,  the  
SHIVA  trial  has  been  called  out  numerous  times  for  its  many  weaknesses.    
   The  first  of  its  many  weaknesses  was  that  many  of  the  patients  used  in  the  
study,  especially  those  with  metastatic  cancers,  were  likely  to  have  more  than  
one  genomic  aberration  in  their  cancer  (Tsimberidou  &  Kurzrock,  2015).  Prior  to  
the  publication  of  the  SHIVA  study  results,  the  team  of  Janku  et  al.  (2014)  
showed  that  patients  with  PI3K/Akt/mTOR  pathway  aberrations,  had  increased  
responses  to  combinatorial  therapy  as  opposed  to  monotherapy.  It  was  therefore  
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called  out  that  the  use  of  monotherapy  in  this  group  of  patients  would  
consequently  be  inappropriate.  Furthermore,  without  considering  other  
alterations  in  the  patient’s  cancer,  one  is  likely  assuming  that  the  alteration  being  
targeted  is  the  only  driver  of  that  patient’s  cancer.  Not  only  is  it  believed  that  a  
typical  tumor  has  two  to  eight  driver  gene  mutations  (Vogelstein  et.  al.,  2013),  but  
that  the  presence  of  additional  alterations  in  the  tumor  genome  can  actually  alter  
the  effectiveness  of  a  certain  treatment.  For  example,  in  a  response  to  the  
Lancet’s  publication  of  the  SHIVA  trial,  Drs.  Tsimberidou  and  Kurzrock  (2015)  
pointed  out  that  the  use  of  everolimus  in  patients  with  PI3K/Akt/mTOR  pathway  
alterations  may  not  only  result  in  limited  responses,  but  if  the  patients  were  to  
also  have  RAF/MEK  alterations,  a  lack  of  response  was  much  more  likely  to  be  
reported.  A  similar  lack  of  response  has  been  seen  in  patients  with  colorectal  
cancer.  Patients  with  colorectal  cancer  often  have  EGFR  mutations,  for  which  
cetuximab  -­  a  monoclonal  antibody  that  binds  to  EGFR  -­  would  be  prescribed  
(Misale  et.  al.  2012).  However,  in  cases  where  these  patients  also  have  KRAS  
mutations,  a  secondary  resistance  is  developed  after  they  initially  show  a  
response  to  cetuximab.  These  discrepancies  point  to  the  complexities  of  
interpreting  genomic  results.  When  genomic  alterations  are  considered  on  a  
gene-­by  gene  basis,  rather  than  within  the  context  of  a  constellation  of  the  
tumor’s  genomic  alterations,  the  interpretation  can  be  overly  simplistic  and  may  
lead  to  less  effective  treatment  for  the  patient.  
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   Although  the  SHIVA  trial  was  followed  up  by  many  published  pieces,  many  
of  which  pointed  out  the  limitations  in  the  study  or  issues  with  the  authors’  
conclusions,  it  is  unknown  to  what  extent  readers  of  the  SHIVA  trial  knew  of  
these  response  articles.    Although  the  SHIVA  trial’s  publication  in  Lancet  did  
concede  to  many  of  the  short-­comings  related  to  the  study’s  design,  it  was  the  
conclusiveness  with  which  the  study’s  authors  found  that  targeted  therapy  
provided  little  to  no  benefit  compared  to  standard  of  care  that  hurts  the  
progressing  field  of  genomic  medicine.    Physicians  are  notoriously  overworked  
and  have  little  time  to  learn  new  material  in  this  field  (Laine  &  Weinberg  1999).    
Without  the  time  to  truly  grasp  the  intricacies  of  the  SHIVA  trial  and  its  
subsequent  commentaries,  oncologists  today  are  susceptible  to  gaining  one,  
rather  than  all  the  necessary  perspectives  of  complicated  scenarios  in  genomics.    
Continued  spread  of  misinformation  by  substandard  genomic  research  will  
accomplish  nothing,  but  stalling  the  complete  utilization  of  comprehensive  
genomic  testing  in  the  oncology  clinic.    
   Further  driving  the  underutilization  of  genomic  information  is  the  speed  at  
which  researchers  have  embraced  cancer  genomics.  In  short,  genomic  research  
has  eclipsed  medical  education  (Xie  &  Frueh,  2005).    
In  the  short  time  genomics  has  been  employed  to  profile  cancers,  there  
has  been  a  swift  decline  in  testing  costs  and  concurrent  increase  in  data  
collection  capacities,  which  has  propelled  the  creation  of  an  overabundance  of  
genomic  data  that  even  today’s  computational  technologies  are  unable  to  
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completely  handle  (Figure  5).    Since  physicians  do  not  yet  have  the  tools  to  make  
sense  of  all  the  data  available  to  them,  one  of  the  most  important  changes  a  
physician  can  employ  in  the  short-­term  will  be  to  strengthen  their  understanding  
and  knowledge  of  cancer  genomics.    
   Physicians  in  all  fields  of  medicine  struggle  to  keep  abreast  of  the  medical  
knowledge  necessary  to  effectively  treat  patients  (Laine  &  Weinberg  1999).  Not  
only  must  physicians  in  oncology  maintain  a  basic  knowledge  set,  they  now  are  
forced  to  build  upon  this  foundation  a  new  set  of  genomic  knowledge  that  grows  
every  day.  Physicians  are  overworked  and  have  minimal  time  to  dedicate  to  
strengthening  their  knowledge  base  (Laine  &  Weinberg,  1999).    What  time  an  
oncologist  does  have  for  reading  is  likely  spent  exploring  synopses  of  science  
publications,  which  likely  come  of  one  of  only  a  few  favorite  journals  (Laine  &  
Weinberg  1999).    This  lack  of  advancement  in  medical  oncology  education  is  
troubling  not  only  because  genomics  in  oncology  is  generating  so  much  new  
information,  but  more  so  it  is  the  fact  that  current  medical  oncologists  are  simply  
outdated  in  their  approach  to  cancer.  It  is  no  longer  enough  to  simply  classify  a  
tumor  based  on  its  tissue  of  origin.    
  
A  NEED  FOR  STANDARDIZATION  
As  oncological  medicine  moves  from  current  histology-­based  approaches  
to  one  rooted  in  genomics,  the  focus  on  realizing  the  full  potential  of  cancer  
precision  medicine  rests  on  creating  an  integrated  classification  system  
	  24	  
(Stenzinger  et.  al.  2015).    The  lack  of  standardized  terms  for  the  practice  of  
genomic  medicine  has  not  been  lost  on  researchers.  Not  only  are  there  issues  
behind  the  interchanging  of  precision  medicine  and  personalized  medicine,  but  
also  behind  the  terms  physicians  are  using  in  the  clinic  to  describe  multiplex  
testing:  molecular  testing;;  tumor  profiling;;  genetic  testing;;  biomarker  testing;;  
tumor  fingerprinting;;  molecular  biology  testing;;  personalized  therapy  testing  
(Gray  et.  al.  2014).  To  further  drive  the  confusion,  these  mixed  terms  are  then  
passed  on  to  the  patients  who  are  already  at  a  handicap  for  understanding  the  
genomics  of  their  conditions.    
Studies  in  breast  cancer  have  shown  that  women  have  limited  cognizance  
of  genomic  testing  (Tzeng  et.  al.  2010).  In  an  article  published  in  the  Journal  of  
Oncology  Practice,  Gray  et  al.  (2012)  studied  patients’  attitudes  towards  genomic  
profiling.  In  the  study,  it  was  discovered  that  less  than  half  (48%)  of  participants  
were  aware  of  the  phrase  personalized  medicine.  Similarly,  those  who  were  at  
least  familiar  with  personalized  medicine  provided  a  number  of  different  
definitions.  Interestingly,  almost  one-­fifth  (19%)  of  the  participants  defined  
personalized  medicine  as  something  unrelated  to  genomics  or  individualized  
treatments  (Gray  et.  al.,  2012).  This  group  of  participants  defined  the  phrase  as  
one’s  ability  to  purchase  medications  over  the  counter,  or  having  consistent  
communication  with  their  physician.      
Although  less  than  half  the  participants  were  aware  of  genomic  testing,  
almost  three-­quarters  (74%)  of  participants  were  aware  of  cancer  genetic  tests  
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and  almost  all  (96%)  of  participatory  patients  would  be  willing  to  have  the  testing  
(Gray  et.  al.,  2012).  That  said,  if  a  full  genome  test  was  offered,  patients  (62%)  
became  significantly  more  hesitant  (Gray  et.  al.,  2012).  While  patients  were  able  
to  see  benefit  in  the  more  narrowed  scope  of  the  somatic  predictive  testing,  
patients  suddenly  cited  “information  overload”  or  “too  much  information  about  
non-­cancer  disease”  (Gray  et.  al.,  2012).  When  asked  to  elaborate  why  they  
would  have  reservations  toward  undergoing  genomic  testing,  patient  responses  
mirrored  the  reasons  physicians  show  caution  when  ordering  genomic  tests.  
Uncertain  benefit,  concerns  over  test  accuracy,  and  misunderstanding  of  the  
procedures  are  working  against  the  goals  of  the  precision  medicine  movement  
(Gray  et.  al.,  2014).  Standardization  of  terminology  around  multiplex  testing  can  
likely  eliminate  any  confusion  between  physicians,  their  colleagues,  and  their  
patients.    
In  an  attempt  to  not  only  standardize  the  personalized  medicine  
movement  in  oncology,  but  to  also  centralize  its  main  efforts,  the  the  NCI  and  
NHGRI  created  The  Cancer  Genome  Atlas  (TCGA  in  2006  (The  Cancer  Genome  
Atlas,  2016).  The  10-­year  long  TCGA  project  has  sought  to  completely  
characterize  roughly  35  different  adult  cancers,  selecting  about  20  commonly  
diagnosed  cancers  and  15  rarely  diagnosed  cancers.  In  a  2014  publication  in  
Cell  Hoadley  et.  al.,  (2014)  from  the  TCGA  project  were  able  to  report  that  1  in  10  
cancers  studied  were  able  to  be  reclassified  using  a  clinically  relevant  genomic-­
based  system.  This  then  allowed  new  therapeutic  options  to  be  offered  that  not  
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have  been  prescribed  through  the  standard  of  care,  tissue-­of-­origin  system  
(Hoadley  et.  al.,  2014).  Additionally,  these  efforts  to  properly  profile  different  
cancers  have  lead  to  increased  clarity  in  the  utility  of  comprehensive  genomic  
testing.  Physician  use  of  such  genomic  tests  vary  given  the  clinical  context  by  
which  they  are  be  used,  the  ordering  of  tests  such  as  OncoMap®,  or  
FoundationOne®  tends  to  rely  on  the  the  type  of  cancer  and  its  staging  (Gray  et.  
al.,  2014).  For  example,  due  to  the  rapid  growth  of  effective  targeted  therapies  
approved  in  non  small  cell  lung  cancer  (NSCLC),  patients  with  NSCLC  lung  may  
be  more  likely  to  have  their  tumors  genomically  profiled,  albeit,  typically  by  a  hot-­
spot  test  screening  for  the  known  or  more  targetable  mutations.  (Magliacane  et.  
al.,  2015).    On  the  other  hand,  a  patient  with  a  less  extensively  studied  cancer,  
like  early  stage  bladder  cancer,  will  have  fewer  options  available  for  a  physician  
to  target  and  would,  ironically,  be  less  likely  to  have  the  genomic  testing  ordered  
(Gray  et.  al.,  2014).  Weighing  genomic  testing  decisions  on  the  assumed  
likelihood  of  discovering  a  targetable  alteration  is  of  a  significant  cause  for  
concern.  This  is  especially  the  case  for  when  the  cancer  type  is  considered  rare.  
A  rare  cancer  is  defined  by  having  an  incidence  rate  of  <6/100,000  per  
year  (Gatta  et.  al.,  2011).  When  considering  all  rare  cancers  together,  “rare”  
seems  to  be  a  less  apt  moniker.  In  at  least  two  different  reports,  researchers  
found  that  rare  cancers  made  up  over  20%  of  all  new  cancer  diagnoses  each  
year  (Gatta  et.  al.,  2011,  Greenlee  et.  al.,  2010).  Considering  the  logic  physicians  
currently  employ  when  deciding  to  order  a  genomic  test  for  their  patients,  it  can  
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thus  be  assumed  that  more  than  1  in  every  5  patients  are  not  having  
comprehensive  genomic  testing  due  to  an  assumed  lack  of  targetable  alterations.  
Exacerbating  this,  rare  cancers  are  reported  to  have  a  significantly  worse  5-­year  
survival  rates  than  common  cancers  (47%  vs.  65%)  (Gatta  et.  al.,  2011).  Limited  
comprehensive  profiling  of  rare  tumor  types  will  only  perpetuate  the  limited  
success  physicians  have  in  treating  these  conditions.  
  
GROWTH  OF  PERSONALIZED  MEDICINE  
   Cancer  is  a  disease  of  the  genome.  In  each  cancer,  there  is  a  combination  
of  altered  oncogenes  and/or  tumor  suppressor  genes  that  drive  the  necessary  
molecular  pathways  for  tumor  growth  (Garraway,  Verweij  &  Ballman,  2013).  As  
the  precision  medicine  movement  grows,  the  number  of  agents  approved  for  use  
in  tumors  with  certain  genomic  alterations  will  only  continue  to  rise.  Therapies  
that  were  once  the  exception  will  soon  be  considered  as  the  first  treatment  option  
in  a  number  of  different  cancer  types  (Hertz  &  McLeod,  2016).  
The  genomic  alterations  and  their  subsequent  disruptions  to  the  cellular  
signal  networks  lead  many  to  believe  that  a  combinatorial  approach  to  therapy  is  
necessary  (Magliacane  et.  al.,  2015).  While  recent  evidence  has  shown  in  GIST,  
CML,  HER2+,  RCC  and  BRAF-­mutant  melanoma  that  some  target  inhibitors  are  
sufficient  enough  to  show  proof  of  concept  (Verweij  et.  al.,  2012),  the  argument  
can  be  made  in  these  select  cases  that  precision  medicine  can  produce  fewer  
side-­effects  and  therefore  be  a  fruitful  alternative  to  cytotoxic  chemotherapy.  
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However,  it  seems  that  these  are  more  of  an  exception  to  the  rule  and  that  the  
convolution  of  cancer  pathogenesis,  more  often  than  not,  may  be  too  involved  to  
suggest  that  a  single  targeted  inhibitor  would  be  sufficient  enough  to  show  proof  
of  concept  in  cancer  treatment  (Verweij  et.  al.,  2012).  Sequencing  studies  have  
shown  that  cancer  genomes  are  more  complex  than  the  activity  of  a  single  driver  
alteration  within  an  oncogene  or  tumor  suppressor  gene  (Chmielecki  &  
Meyerson,  2014).  In  solid  tissue  cancers  like  lung  cancer  and  melanoma,  where  
external  insults  have  brought  with  them  numerous  non-­driver  genomic  
alterations,  geneticists  are  left  to  overcome  the  obstacle  of  determining  where  
driver  mutations  end  and  where  background  mutations  begin.    
   Improved  costs  and  efficiency  has  led  to  a  spike  in  the  interest  and  
utilization  of  comprehensive  genomic  testing  outside  the  clinic  (MacConaill,  
2013).  Sequencing  has  built  up  an  immense  pool  of  data  that  is  well-­beyond  the  
skills  of  any  one  physician  or  geneticist  (Chmielecki  &  Meyerson,  2014).    
Over  the  last  few  decades,  the  world  of  genomics  has  been  on  the  
receiving  end  of  a  number  of  technological  improvements,  which  has  allowed  the  
field  to  move  quickly,  and  drastically  from  the  single-­gene  sequencing  Sanger  
method,  to  massively  parallel  comprehensive  genomic  profiling  of  hundreds  of  
genes  (Chmielecki  &  Meyerson,  2014).  Today,  in  thanks  to  these  advancements  
in  targeting  technologies  and  significantly  improved  computing  tools,  geneticists  
can  now  read  the  entire  sequence  of  a  genome  at  a  relatively  low  price  (Campo,  
2013)  (Figure  5).  Furthermore,  the  technology  has  become  so  advanced  that  
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scientists  are  now  able  to  read  the  DNA  exomes,  which  are  portions  of  the  
genome  that  encode  proteins,  as  well  as  the  mRNA  transcripts  created  from  
one’s  genome;;  the  transcriptome  (Chmielecki  &  Meyerson,  2014).  
  
  
Figure  5.  The  evolution  of  genomic  sequencing  technologies  have  allowed  
increased  data  throughput  while  associated  costs  decrease.  
  





Even  with  its  status  as  a  relative  newcomer  to  the  scene  of  oncological  
treatment  schema,  the  use  of  genomic  data  in  driving  therapy  decisions  has  led  
to  significant  improvements  in  patient  survival.  In  one  study,  by  using  a  patient’s  
prior  therapy  progression-­free  survival  as  control,  Von  Hoff  et  al.,  (2010)  were  
able  to  show  a  progression-­free  survival  ratio  of  1-­3  or  more  in  27%  of  patients  
going  on  matched,  targeted  therapies.  In  other  words,  27%  of  patients  going  on  
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matched  therapies  had  a  progression  free  survival  length  1-­3+  times  longer  than  
when  on  conventional  therapy.  In  a  similar  study  of  breast  cancer  patients,  44%  
of  patients  going  on  matched  therapies  also  showed  a  ratio  of  1-­3  or  more  
(Jameson  et.  al.,  2014).    
Moreover,  this  increase  in  survival  has  been  shown  to  be  associated  with  
the  use  of  matched  therapies  in  lung  cancer  patients  as  well  (Kris  et.  al.,  2014).  
Furthermore,  two  meta-­analyses  reported  higher  proportions  of  patients  
achieving  drug  responses,  and  longer  PFS  and  OS  with  matched  therapies  than  
trials  with  unmatched  patients  (Schwaederle  et.  al.,  2015)  and  (Jardim  et.  al.,  
2015).    
Although  these  studies  are  suggestive  of  supporting  a  personalized  
approach  to  cancer  therapy,  they  are  also  remindful  of  the  limitations  of  current  
matched  therapies.  In  each  of  the  studies  just  described,  significant  effects  in  
favor  of  targeted  therapies  were  found  in  just  a  minority  of  patients.  The  reason  
many  current  tissue-­based  treatment  plans  fail  is  that  they  are  made  under  the  
assumption  that  the  patient’s  tumor  phenotype  was  brought  forth  by  the  abnormal  
functioning  of  one  receptor,  intracellular  pathway  or  signal  protein,  rather  than  
any  number  of  combinations  of  the  three  (Verweij  et.  al.,  2012).  Much  like  that  
seen  in  clonal  B-­cell  neoplasm  in  multiple  myeloma,  it  is  conceivable  that  a  
tumor’s  genetic  instability  may  lead  to  alternative  receptors  or  pathways  
becoming  sequentially  responsible  for  the  malignant  phenotype,  which  could  
confer  delayed  resistance  to  monotherapy  in  select  tumor  types  (Hallek,  
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Bergsagel,  &  Anderson,  1998).    Scientists  are  now  able  to  perform  temporal  
sequencing  studies  of  blood-­borne  diseases  to  observe  the  changes  purported  
over  the  lifetime  of  the  disease  (Landau  et.  al.,  2013).  Future  studies  can  then  be  
used  to  learn  more  about  genomic  variation  that  has  since  been  observed  in  
leukemia,  kidney  cancer  (Gerlinger  et.  al.,  2012),  and  especially  pancreatic  
cancer  in  which  it  was  found  that  variations  in  the  metastatic  lesions  are  reflective  
of  small,  individual  clusters  of  cells  within  the  primary  tumor  (Yachida  et.  al.,  
2010).    
Matched  therapies,  as  with  any  therapy  used,  should  consistently  target  
the  function  of  the  alterations  which  drive  the  patient’s  disease  (Tsimberidou  &  
Kurzrock,  2015).  For  patients  with  more  advanced  conditions,  or  with  cancers  -­  
such  as  NSCLC  -­  known  to  have  higher  mutation  loads,  combination  regimens  
should  be  used  (Tsimberidou  &  Kurzrock,  2015).  In  order  to  effectively  prescribe  
combination  treatment  plans,  physicians  will  need  access  to  a  growing  number  of  
targeted  therapies.  A  significant  piece  to  the  growth  of  the  precision  medicine  
movement  will  be  the  continued  efforts  from  the  pharmaceutical  companies  to  
build  up  a  surplus  of  treatment  options  for  future  cancer  patients.    
  
PHARMACEUTICAL  EFFORTS  
   Although  the  cancer  drug  landscape  has  been  evolving  over  the  last  few  
decades,  the  area  of  personalized  medicine  has  seen  a  dramatic  change  in  the  
pharmaceutical  field.  Since  the  start  of  the  genomic  revolution  in  cancer  care,  
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there  has  been  a  dramatic  increase  in  the  number  of  targeted  cancer  drug  
approvals  (Figure  6).    
  
  
Figure  6.  Cancer  drug  approvals  per  year    
  
(From  Masters  et.  al.,  2015)  
  
   In  2014,  the  FDA  approved  41  drugs,  9  of  which  were  personalized  
medicines.  In  2015,  this  number  almost  doubled  to  17  (Food  and  Drug  
Administration,  2015).  Thirty-­five  percent  (6/17)  of  the  personalized  drugs  
approved  in  2015  were  for  cancer.  Behind  these  changes  are  the  investments  in  
personalized  medicines  by  pharmaceutical  companies  (Kaitlin,  2015).  Improved  
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costs  and  efficiency  has  led  to  a  spike  in  the  interest  and  utilization  of  
comprehensive  genomic  testing  outside  the  clinic  (MacConaill,  2013).    
Biopharmaceutical  firms  last  year  projected  that  over  the  next  five  years  
investment  in  personalized  medicines  will  increase  by  33%  and  medicines  in  
development  by  69%  (Kaitlin  2015).    Continued  investment  in  drug  development  
by  the  pharmaceutical  companies  is  of  the  utmost  importance  as  a  number  of  
significant  challenges  to  personalized  medicine  still  remain.  Biomarker  
identification,  and  diagnostic  test  development  are  vital  for  future  understanding  
of  the  utility  of  genomic  medicine,  while  regulatory  oversight,  and  reimbursement  
remain  as  barriers  to  delivering  precision  medicine  to  patients  (Kaitlin,  2015).  It  
should  not  be  understated  however,  that  the  success  in  the  realm  of  research  
and  development  is  necessary,  but  not  sufficient,  to  overcome  regulatory  and  
reimbursement  oversight  (Kaitlin,  2015).    When  physicians  are  hesitant,  fewer  
cases  are  reportable  for  clinical  utility,  not  only  stagnating  growth  in  genomic  









Table  1:  FDA  approved  targeted  therapies  across  multiple  cancer  types  




therapies	   Example	  therapy	  
Adenocarcinoma	  of	  the	  stomach	  or	  
gastroesophageal	  junction  
2	  
	  Trastuzumab	  (Herceptin®)  
Basal	  cell	  carcinoma   2	   	  Vismodegib	  (Erivedge®)  
Brain	  cancer   2	   	  Bevacizumab	  (Avastin®)  
Breast	  cancer   12	   	  Everolimus	  (Afinitor®)  
Cervical	  cancer   1	   	  Bevacizumab	  (Avastin®)  
Colorectal	  cancer   6	   	  Cetuximab	  (Erbitux®)  
Dermatofibrosarcoma	  protuberans   1	   	  Imatinib	  mesylate	  (Gleevec®)  
Endocrine/neuroendocrine	  tumors  
1	   	  Lanreotide	  acetate	  
(Somatuline®	  Depot)  
Head	  and	  neck	  cancer   1	   Cetuximab	  (Erbitux®)  
Gastrointestinal	  stromal	  tumor   3	   Imatinib	  mesylate	  (Gleevec®)  
Giant	  cell	  tumor	  of	  the	  bone   1	   Denosumab	  (Xgeva®)  
Kaposi	  sarcoma   1	   Alitretinoin	  (Panretin®)  
Kidney	  cancer   8	   Sunitinib	  (Sutent®)  
Leukemia   12	   Tretinoin	  (Vesanoid®)  
Liver	  cancer   1	   Sorafenib	  (Nexavar®)  
Lung	  cancer   12	   Erlotinib	  (Tarceva®)  
Lymphoma  
14	   Ibritumomab	  tiuxetan	  
(Zevalin®)  
Melanoma   7	   Ipilimumab	  (Yervoy®)  




Imatinib	  mesylate	  (Gleevec®)  
Neuroblastoma   	   Dinutuximab	  (Unituxin™)  
Ovarian	  epithelial/fallopian	  
tube/primary	  peritoneal	  cancers  
2	  
Bevacizumab	  (Avastin®)  
Pancreatic	  cancer   3	   Everolimus	  (Afinitor®)  
Prostate	  cancer   4	   Cabazitaxel	  (Jevtana®)  
Soft	  tissue	  sarcoma   1	   Pazopanib	  (Votrient®)  
Systemic	  mastocytosis   1	   Imatinib	  mesylate	  (Gleevec®)  
Thyroid	  cancer   4	   Cabozantinib	  (Cometriq®)  





The  precision  medicine  movement  has  brought  with  it  unparalleled  
advances  in  translational  cancer  research  (Garraway,  2013).    In  order  to  
progress  further,  key  principles  need  to  take  hold.  First,  there  needs  to  be  
consensus  understanding  that  the  molecular  pathways  that  drive  tumor  growth  
and  suppress  death  are  turned  on  by  genetic  aberrations.  Second,  robust  
profiling  of  many  different  tumor  types  is  necessary  to  wholly  understand  the  
cancer  being  treated.  Finally,  there  needs  to  be  consensus  understanding  that  
‘big  data’  associated  with  the  profiling  of  many  different  tumor  types  is  not  
enough  to  fully  revolutionize  cancer  care  in  the  US  (Garraway,  2013).  A  fully  
recognized  revolution  in  the  field  of  cancer  genomics  still  needs  improved  
treatments,  improved  diagnostics,  and  improved  medical  education  (Garraway,  
2013).  
   Medicine,  as  we  know  it  today,  revolves  around  “standards  of  care”,  which  
are  guidelines  for  physicians  in  treating  the  general  public.  Historically,  in  cancer,  
these  standards  have  meant  surgery,  radiation,  and  a  trial-­by-­error  regimen  of  
chemotherapy  (Duffy  &  Crown,  2008).  After  a  tumor  is  located  and  analyzed,  the  
aberrant  tissue  is  often  excised  to  the  best  of  the  surgeon’s  ability  (Senkus  et.  al.,  
2015).  Since  the  surgeon  cannot  say  for  certain  that  all  cancerous  cells  have  
been  removed,  the  patient  is  then  ushered  into  the  next  stage  of  cancer  
treatment:  cytotoxic  therapy.  While  the  surgeon’s  excision  of  tissue  is  a  precise  
approach  to  cancer  treatment,  an  oncologist’s  chemotherapy  is  not.  Rather,  the  
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chemotherapy  targets  not  just  the  cancer  cells,  but  typically  all  cells  around  it  
(Mendelsohn  et.  al,  2015).  Even  if  the  tumor  cells  are  only  a  minor  subset  of  the  
population  of  cells  in  a  set  area,  the  chemotherapy  will  cast  a  wide  net  in  the  
hopes  that  by  including  the  other  cells,  it  has  also  targeted  the  cancer  as  well.  
Due  to  its  diffuse  approach  to  treatment,  the  cytotoxicity  of  the  chemotherapy  
leads  to  significant  side  effects  (Partridge,  Burstein,  &  Winer,  2001).    Even  
worse,  not  all  chemotherapies  are  highly  effective.  Cytotoxic  chemotherapies,  on  
average,  are  effective  just  over  20%  of  the  time  (Morgan,  Ward,  &  Barton,  2004).  
Although  chemotherapy  has  the  lowest  success  rate,  it  should  be  noted  that  
cancer  treatments,  as  a  whole,  are  not  significantly  more  effective.  Of  different  
therapeutic  areas  studied,  cancer  has  the  lowest  efficacy  rate  across  approved  
therapies  (Table  2).  
  
Table  2.  Efficacy  rates  of  drugs  approved  in  select  indications  
Therapeutic  Area   Rate  of  Response  
Alzheimer’s  disease   30%  
Analgesics   80%  
Asthma   60%  
Cancer   25%  
Cardiac  arrhythmias   60%  
Depression  (SSRI)   62%  
Diabetes   57%  
Migraine  (acute)   52%  
Rheumatoid  arthritis   50%  
(Adapted  from  Spear,  Heath-­Chiozzi,  &  Huff,  2001).  
  
   As  pathologists  and  oncologists  today  continue  to  diagnose  patients  under  
an  outdated,  tissue-­based  approach,  patients  are  left  spinning  the  wheel  of  fate  
	  37	  
as  a  trial-­by-­error  treatment  regimen  is  prescribed.  It  is  an  unfortunate  process  of  
discovering,  one-­by-­one,  the  effectiveness  of  standard-­of-­care  treatments  for  
each  patient  using  largely  ineffective  treatments  that  often  have  significant  side-­
effects.    Unfortunately,  many  patients,  especially  those  with  the  most  aggressive  
cancers  (i.e.,  pancreatic,  lung  or  brain),  do  not  match  to  a  successful  treatment  
until  their  3rd  or  4th  line  therapy  (Hanker  et.  al.,  2012).  The  future  of  precision  
medicine  rests  on  being  able  to  match  patients  to  a  successful  therapy  as  their  
first  choice.    
     
CANCER  SCREENING  
   For  cancer  patients,  the  answer  may  not  rest  with  increased  cancer  
screening.    A  meta-­analysis  found  that  healthy  individuals  who  were  screened  for  
diseases  where  there  is  a  significant  risk  of  mortality  showed  no  significant  
reductions  in  disease-­related  deaths  (Saquib,  Saquib,  &  Ioannidis,  2015).    
Although  the  breadth  of  this  study  extended  beyond  just  different  cancers,  it  is  
significant  to  note  of  its  conclusion  as  there  remains  limited  options  for  healthy  
individuals  to  prepare  for  cancer.  
   Recently,  there  have  been  a  few  high-­profile  examples  of  healthy  
individuals  using  genomics  to  give  themselves  the  upper  hand  in  battling  cancer.    
In  2013,  after  discovering  that  she  carried  the  same  genetic  marker  for  breast  
cancer,  a  disease  that  killed  her  mother,  actress  Angelina  Jolie  underwent  a  120-­
year  old  procedure  to  remove  most  of  the  tissue  from  both  breasts  (McMullan,  
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2015).  Lauded  by  some,  and  condemned  by  many  others,  Mrs.  Jolie  undertook  
the  radical  procedure  after  genomic  tests  revealed  that  she  carried  the  BRCA1  
mutation,  a  genetic  marker  found  in  65%  of  all  breast  cancers  (McMullan,  2015).  
Although  it  is  not  recommended  as  a  first-­line  preventative  measure  for  women  
carrying  the  BRCA1  alteration,  Mrs.  Jolie’s  action  speaks  volumes  to  the  power  
of  genomics  in  helping  place  the  power  in  the  patient’s  hands  in  the  fight  against  
cancer.  Though  today  the  field  of  cancer  genomics  cannot  arm  all  patients  with  a  
power  similar  to  Mrs.  Jolie,  it  can  however  continue  to  build  an  arsenal  of  
knowledge  that  will  forever  shape  cancer  care  for  generations  to  come.    
   The  seed  of  precision  medicine  has  been  planted,  but  for  it  to  grow,  it  
must  be  watered  with  high-­quality  genomic  information  (Lopez-­Chavez  et.  al.,  
2015).  As  the  budding  field  of  genomics  enters  the  resident  field  of  oncology,  it  
must  be  amenable  to  the  changes  necessary  for  success.  Although  oncologists  
fundamentally  agree  that  patients  do  respond  differently,  it  is  hard  to  make  
changes  in  a  conventional  system.  Physicians  want  substantive  evidence  before  
they  move  away  from  trial-­by-­error  system  of  traditional  medicine  (McMullan,  
2015).  To  be  effective,  genomics  must  prove  to  physicians  that  this  new  
information  is  an  improvement.    
   The  first  step  for  genomics  to  supplant  the  traditional  approach  to  treating  
cancer  patients  will  be  the  generation  of  extensive  evidence  supporting  the  utility  
of  genomics  in  oncology.  In  order  to  generate  this  information,  significant  
changes  need  to  take  hold  in  design  of  clinical  trials.  
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IMPROVED  CLINICAL  TRIALS  
 
Thus  far,  tens  of  thousands  of  genomic  alterations  have  been  discovered  
in  patient  tumors  (Friedman  et.  al.,  2015).  Even  in  the  relatively  few  years  that  
tumors  have  been  genomically  profiled,  it  is  believed  that  all  the  “low-­hanging  
fruit”  of  driver  mutations  have  been  picked,  and  that  we  are  now  essentially  
looking  at  the  long  tail  end  of  the  list,  made  of  rare  alterations  (Friedman  et.  al.,  
2015).  Most  mutations  that  affect  large  populations  of  patients  have  been  found  
and  have  driven  drug  discovery  in  today’s  current  model  of  clinical  trials  
(Friedman  et.  al.,  2015).  Thousands  of  mutations  remain  that  have  not  been  fully  
categorized  in  terms  of  their  functional  consequences  in  tumors  because  the  
current  clinical  trial  model  supports  testing  only  those  mutations  that  are  found  in  
large  populations  (Friedman  et.  al.,  2015).  No  matter  the  number  of  available  
mutations  for  categorization,  the  fact  that  they  reside  at  the  long  tail  end  of  the  list  
means  that  they  are  rare  in  the  general  cancer  population  and  will  require  tailored  
approaches  to  study.    
   Currently,  there  are  efforts  being  made  to  improve  how  clinical  trials  are  
conducted  in  oncology.    A  typical  oncological  clinical  trial  focuses  on  one  drug,  in  
one  tumor  type.  This  has  not  only  proven  time  consuming,  but  significant  
evidence  has  been  presented  suggesting  that  this  approach  is  wasteful  as  
monotherapy  has  shown  to  be  less  effective  than  combinatorial  approaches  
(Tsimberidou  &  Kurzrock,  2015).    Additionally,  clinical  trials  -­  although  an  option  
for  many  patients  looking  to  try  new  therapies  -­  are  not  always  met  with  success.  
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In  fact,  between  2003  and  2010  only  9%  of  the  4,275  clinical  trials  conducted  
ended  with  approval  for  the  trial  drug  or  intervention  (Zhang  &  Lee,  2014).      
   As  a  result  of  such  findings,  researchers  in  oncology  are  shifting  to  a  more  
genomic-­based  paradigm.  In  one  example,  the  “basket  trial”  is  being  utilized  to  
target  the  idea  that  specific  genomic  alterations  can  be  found  in  many  tumor  
types  (Rajiv  &  Kapil,  2010).  A  select  therapy  may  prove  effective  in  different  
tumor  types  if  the  therapy  targets  genomic  alterations  shared  by  the  two  (Lopez-­
Chavez  et.  al.,  2015).    For  example,  basket  trials  are  built  to  test  an  EGFR  
inhibitor  regardless  if  the  EGFR  alteration  was  found  in  lung,  colon,  breast,  or  
liver  tissue  (Figure  7).    This  approach  is  more  effective  at  discerning,  for  
instance,  that  RAF  inhibitors  in  a  BRAF[V600]-­mutant  melanoma  will  respond  
quite  differently  when  used  against  BRAF[V600]-­mutant  colorectal  carcinomas  



















Figure  7.  The  basket  trial  design  matches  genomic  alterations  irrespective  of  
tissue  of  origin  
  
(From  Sleijfer,  Bogaerts,  &  Siu,  2013)  
  
Other  scientists  are  further  building  off  the  basket  trial  by  utilizing  the  
longitudinal  cohort  design,  where  large  scale  molecular  profiling  is  utilized  on  
patients  with  different  tumor  types.  The  aim  is  to  drive  future  treatments  off  of  
genomic  profiles  rather  than  single  mutations  or  factors  (Sleijfer,  Bogaerts,  &  Siu,  
2013).    
In  addition  to  the  trial  design,  another  issue  to  consider  is  how  patients  
diagnosed  with  cancer  do  not  automatically  qualify  for  a  clinical  trial.  A  typical  
clinical  trial  will  include  a  number  of  inclusion  and  exclusion  criteria  set  to  help  
narrow  the  patient  type  in  the  trial.  Patients  are  often  excluded  because  of  their  
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age,  their  organ  function,  and  their  performance  level.  This  is  seen  most  
frequently  with  elderly  cancer  patients  or  patients  with  later  stage  cancer  as  they  
typically  have  worse  performance  scales  and  may  not  have  sufficient  organ  
function  (Curley,  2015).  Some  clinical  studies  have  been  designed  to  get  around  
this,  but  they  have  not  been  without  certain  tradeoffs.    
   The  CUSTOM  trial  was  a  basket  trial  that  allowed  enrollment  of  patients  of  
multiple  histologic  subtypes  (Lopez-­Chavez  et.  al.,  2015).    The  study  of  NSCLC,  
SCLC  and  thymic  malignancies  allowed  patients  with  any  organ  function,  any  
ECOG  performance  status,  and  any  number  of  previous  therapies.  As  a  result,  
the  trial  was  able  to  accrue  over  640  patients  in  just  20  months  (Lopez-­Chavez  
et.  al.,  2015).  Handling  each  treatment  arm  as  its  own  independent  phase  II  trial,  
the  goal  was  to  evaluate  each  of  five  drugs  in  the  three  histologic  subtypes  
without  requiring  a  large  number  of  patients.  The  study  had  significant  limitations.    
   The  CUSTOM  trial  was  perhaps  overly  ambitious,  while  also  being  too  
focused.  By  opening  the  inclusion  and  exclusion  criteria,  the  investigators  were  
left  with  significant  heterogeneity  in  the  tumor  samples  provided  for  profiling  
(Lopez-­Chavez  et.  al.,  2015).    Without  the  luxury  of  comprehensive  genomic  
profiling,  the  molecular  tests  performed  in  the  CUSTOM  trial  varied  significantly.  
Additionally,  for  patients  with  worse  performance  status,  or  later  stage  cancers,  
any  significant  delays  that  were  a  result  of  the  molecular  profiling  were  met  with  
patients  going  on  traditional  therapies  prior  to  getting  test  results  (Lopez-­Chavez  
et.  al.,  2015).    Because  the  trial  was  set  up  at  only  two  centers,  the  investigators  
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were  limited  in  the  pool  of  patients  available  for  study  participation  (Lopez-­
Chavez  et.  al.,  2015).    After  it  all,  it  became  obvious  that  one  of  the  reasons  the  
CUSTOM  trial  was  not  successful  was  because  its  lack  of  flexibility  (Lopez-­
Chavez  et.  al.,  2015).  
Though  basket  trials  allow  investigators  to  observe  a  wider  patient  
population  looking  at  the  effectiveness  of  a  choice  therapy,  and  an  adjustment  of  
inclusion  criteria  can  increase  patient  enrollment,  perhaps  the  ideal  design  would  
have  been  to  allow  the  investigator  to  use  real-­time  information  to  select  the  best  
treatment  available  for  newly  enrolled  patients,  while  maintaining  the  integrity  of  
the  study.  In  other  words,  to  use  the  adaptive  clinical  trial  design  (Table  3).  
An  adaptive  trial  design  circumvents  risk  by  accumulating  data  on  an  
ongoing  basis,  permitting  the  investigators  to  drive  the  reformulation  of  trial  arms  
(Zhang  &  Lee,  2014).  Doses  can  be  increased  or  decreased  in  the  adaptive  trial  
design.  Select  trial  arms  may  be  closed  if  unable  to  meet  their  efficacy  goals,  or  
adjusted  to  allow  for  randomization  or  to  utilize  other  determinants  of  treatment  
allocation  (Zhang  &  Lee,  2014).  Potential  changes  to  the  adaptive  trial’s  design  
are  agreed  upon  ahead  of  time  by  various  review  boards  and  therefore  allow  






Table  3.  Feature  comparison  of  conventional  and  adaptive  trials.  
Features   Conventional  Trial   Adaptive  Trial  
Design   More  rigid   Flexible  
Treatment  arms   Maximum  2-­3     1-­3  or  more  
Hypothesis   Test  the  hypothesis   Fit  data  into  a  hypothesis  
Modifications   Allowed  under  amendments   Pre-­specified  
Phases   Phases  I-­II  are  well  defined   Can  be  seamless  phase  II-­
III  design  
Organization   Simple   Complicated,  requiring  
simulations  
Interim  analysis   Not  performed  routinely   Performed  routinely  
Role  of  independent  data-­
monitoring  committee  
Typically  at  end  of  trial   Active  throughout  trial  
(Adapted  from  Rajiv  &  Kapil,  2010)  
Since  a  major  challenge  in  therapeutics  world  is  how  patient  responses  to  
drugs  can  vary  the  conventional  trial  design  results  with  many  failed  compounds  
(Woodcock,  2016).    By  being  able  to  adapt,  and  perhaps  predict  this  variability  in  
patients,  adaptive  trials  can  be  used  to  decrease  the  number  of  patients  on  
ineffective  compounds  at  ineffective  doses,  and  help  to  curtail  extraneous  
spending  on  behalf  of  the  study  sponsors  (Rajiv  &  Kapil,  2010).    
The  adaptive  trial  design  in  oncology  clinical  trials  will  help  maximize  
efficiency  as  ineffective  drugs  are  removed  from  further  consideration.  This  
allows  pharmaceutical  companies  to  focus  on  more  drugs  of  promise,  which  will  
in  turn  further  drive  forward  personalized  medicine.       
   One  oft  under-­emphasized  point  around  clinical  trials  is  that  more  than  the  
costs  of  medications,  the  most  significant  barrier  to  patients  getting  on  treatments  
is  accessibility  to  clinical  trials  (Nipp,  Powell,  Chabner  &  Moy,  2015).    Patients  
are  often  treated  in  the  community  setting,  which  is  less  likely  to  have  a  relevant  
clinical  trial  open  as  compared  to  a  large  academic  medical  center  (Institute  of  
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Medicine,  2010).  Many  patients  have  to  weigh  the  monetary  costs  associated  
with  traveling  to  a  clinical  trial  center  in  order  to  receive  treatment.    Two-­hundred  
dollars  to  six-­hundred  dollars  a  month  in  costs  associated  with  travel  pale  in  
comparison  to  the  research  costs  covered  by  the  study  sponsor,  yet  represent  a  
significant  barrier  to  patients  who  are  already  overwhelmed  by  treatment-­
associated  costs  (Nipp,  Powell,  Chabner  &  Moy,  2015).  Clinical  trials  need  to  not  
only  be  adaptive  in  design,  but  also  in  their  overall  approach  to  the  greater  
oncological  community.    
  
INTERIM  NEED  FOR  SUPPORT  
 
“The  big  question  right  now  is  ‘How  do  we  take  all  this  new  
information  we’re  gathering  and  use  it  for  the  benefit  of  the  
patient?’”    
          -­  J.  Leonard  Lichtenfeld,  (Friedman  et.  al.,  2015)  
  
In  early  February  of  2015,  President  Barack  Obama  released  his  Precision  
Medicine  Initiative,  a  $215-­million-­dollar  plan  to  help  further  develop  
personalized,  genomics-­based  treatments  (Friedman  et.  al.,  2015).  For  reasons  
stated  above,  the  excitement  around  personalized  medicine  has  dramatically  
outpaced  its  incorporation  into  the  world  of  oncology,  which  means  most  patients  
are  likely  not  yet  receiving  customized  care.    Since  many  doctors  are  not  
qualified,  or  are  hesitant  to  derive  utility  from  the  genomic  tests,  many  will  likely  
turn  to  colleagues  for  clarity  (Perley,  2006).  This  has  been  an  area  of  concern  as  
the  majority  of  patients  are  treated  in  community  hospital  settings  and  not  at  big  
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academic  medical  centers.  Consequently,  as  reported  by  Gray,  et.  al.,  (2014)  
colleagues  who  are  well  versed  in  cancer  genomics  are  few,  and  far  between.  In  
the  interim,  oncologists  are  likely  to  then  turn  to  the  very  companies  that  are  
providing  the  genomic  testing  results.  Oncologists  turning  to  companies  can  be  a  
cause  for  concern.  Although  being  heavily  regulated,  these  companies  do  have  
financial  motives.    There  have  been  situations  whereby  3rd  party  genomic  
companies  have  overstepped  their  ability  in  generating  reliable  genetic  
information  (Gutierrez,  2014).  The  future  of  cancer  genomics  relies  on  these  
companies  to  not  only  provide  quality  testing  results,  but  also  their  services  as  
facilitators  of  ever-­evolving  genomic  knowledge.  Reliance  on  simply  one  source  
should  never  be  advised  however,  short  term  utilization  of  such  companies  
should  be  looked  at  as  a  crutch,  rather  than  a  comprehensive  fix  to  the  issues  
surrounding  genomic  education  of  oncologists.    
   Both  precision  and  personalized  cancer  medicine  are  still  in  their  infancy  
and  their  growth  will  be  challenged  over  the  next  few  years.  A  complete  
incorporation  of  genomics  into  the  world  of  oncology  will  require  substantial  
resources.  Right  now,  only  a  few  large  academic  medical  centers  have  the  
resources  necessary  to  establish  a  significant  in-­house  tumor  testing  program  
(Cheng  et.  al.,  2015).  Therefore,  only  a  small  number  of  centers  can  treat  
patients,  process  tumor  tissue  samples,  analyze  genomic  alterations,  and  
subsequently  run  the  necessary  computational  interpretations,  all  while  under  
significant  time  and  quality  control  constraints  (Hertz  &  McLeod,  2016).  Having  
	  47	  
everything  under  one  roof  is  ideal  for  the  patients  of  these  large  centers,  yet  does  
little  for  the  number  of  patients  who  are  treated  outside  these  large  centers.  The  
solution  to  helping  these  patients  is  simple.  The  collaboration  between  the  
community  oncologist  and  the  third-­party  genomic  testing  provider  must  occur.  It  
is  for  the  best  of  the  precision  medicine  movement.    
   Future  large-­scale  efforts  in  genomic  testing  will  generate  a  surfeit  of  data  to  
be  analyzed  (Figure  5).  Fortunately,  third-­party  genomic  testing  companies  are  
armed  with  the  tools  necessary  to  help  take  on  the  significant  burden  of  cancer  
profiling,  and  can  package  the  relevant  information  for  the  physician  to  use  
(Foundation  Medicine,  2016).  Open  communication  between  physicians  and  
genomic  testing  companies  will  allow  increased  clinical  utility  of  tumor  testing  
(Hertz  &  McLeod,  2016).      
   Foundation  Medicine  (Cambridge,  MA)  is  a  biomedical  information  company  
that  performs  comprehensive  genomic  profiling  in  solid  and  hematological  
cancers.  A  comprehensive  genomic  profile  of  solid  tumors  performed  at  
Foundation  Medicine,  Inc.  will  sequence  over  300  different  genes  for  four  major  
genomic  alterations  (Foundation  Medicine,  2016).  In  place  of  the  oncologist  
staying  abreast  of  every  technological  breakthrough  in  precision  cancer  
medicine,  the  genomic  testing  company  can  be  employed  to  give  the  healthcare  
provider  only  the  most  relevant  of  information  for  each  of  their  patients.  Through  
harnessing  both  computational  biology  and  the  latest  advancements  in  genomic  
testing,  a  bioinformatics  company  can  be  utilized  for  its  genomics  education  and  
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treatment  decision  guidance  resources.    
   Reports  generated  from  a  tumor  profile  can  provide  the  oncologist  not  only  
a  list  of  genomic  aberrations  found  in  the  patient’s  tumor,  but  also  a  list  of  any  
available  treatments  for  each  of  the  genomic  alterations.  Companies  like  
Foundation  Medicine  use  peer-­reviewed  research  publications,  and  a  list  of  up-­
to-­date  FDA  approvals  of  targeted  therapies  to  build  a  personalized  report  for  
each  tumor  profile  (Foundation  Medicine,  2016).  For  example,  any  patient  with  
non-­small  cell  lung  carcinoma  and  a  mutation  in  ALK  will  be  matched  with  the  
ALK  inhibitor  crizotinib  because  it  has  shown  to  be  superior  as  a  first-­line  therapy  
as  compared  to  chemotherapy  (Solomon  et.  al.  2014).  Because  of  its  success  in  
targeting  ALK,  crizotinib  can  then  be  suggested  for  any  patient  with  an  ALK  
mutation  -­  as  an  “off-­label”  therapy  -­  if  the  cancer  type  is  not  NSCLC.  
Furthermore,  their  report  can  also  match  the  patient’s  list  of  alterations  with  a  list  
of  all  current  clinical  trials  that  are  accepting  patients  with  the  same  alterations  
(Foundation  Medicine,  2016).      
   Why  companies  like  Foundation  Medicine  are  poised  to  become  facilitators  
of  genomic  information  is  because  when  physicians  receive  a  report,  not  only  is  
the  relevant  information  summarized  on  the  front  page  of  the  genomic  test  report,  
but  there  is  also  a  collection  of  supplementary  material  appended  to  the  report  to  
help  the  physician  better  understand  why  each  medication  or  clinical  trial  was  
matched  to  the  patient  (Foundation  Medicine,  2016).  
   As  a  centralized  laboratory  for  solid  and  hematological  cancer  profiling,  the  
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bioinformatics  companies  are  a  repository  of  genomic  data  for  all  kinds  of  
cancers  affecting  Americans  today.  Even  at  a  major  academic  medical  center,  a  
cancer  researcher  studying  a  specific  rare  cancer  may  see  only  a  handful  of  
cases  each  year.  However,  by  mining  the  database  at  any  one  of  the  genomic  
profiling  companies,  the  researcher  may  find  significantly  more  cases  
(Foundation  Medicine,  2016).    
   Whether  the  physician  is  looking  to  profile  a  patient’s  tumor,  or  educate  
themselves  on  genomic  alterations  or  perhaps  a  rare  tumor  type,  the  ability  of  the  
third-­party  bioinformatics  company  to  be  a  facilitator  of  genomic  information  
cannot  be  understated.  
CONCLUSION  
 
   In  a  time  where  information  overload  is  stagnating  innovation  in  the  
oncology  clinic,  the  use  of  a  third-­party  genomic  profiling  company  as  a  facilitator  
of  genomic  data  and  education  can  prove  extremely  beneficial.    
Despite  these  advances,  we  still  have  much  to  learn  from  DNA  analyses.  
Future  studies  looking  at  pathogenic  sequences,  heterogeneity,  clonal  evolution,  
and  noncoding  mutations  will  enhance  our  understanding  of  what  drives  cancer  
and  reveal  vulnerabilities  ideal  for  therapeutic  intervention  (Chmielecki  &  
Meyerson,  2014).  Further  improvement  in  clinical  trial  design  and  therapeutic  
regulation  will  allow  scientists  to  further  build  on  upon  these  advances,  which  will  
ultimately  lead  to  more  efficacious  treatment  decisions.  Finally,  bioinformatics  
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companies  must  foster  long-­lasting  relationships  with  practicing  physicians  in  
order  to  help  translate  genomics  to  the  clinic.      
Some  regard  genomics  to  have  utility  if  it  can  be  used  immediately  to  
derive  a  positive  outcome,  whereas  others  are  satisfied  with  the  peace  of  mind  
that  comes  from  having  a  diagnosis,  regardless  of  its  outcome  (Delaney  &  
Christman  2016).  Whichever  way  it  is  viewed,  precision  cancer  medicine  is  an  
inevitability.  How  soon  this  inevitability  occurs  will  be  determined  by  those  who  
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